Phosphate-Buffered Saline (PBS, pH 7.4), penicillin–streptomycin, and ROS detecting probe were purchased from Keygen (Nanjing, China). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640, and trypsin were purchased from Thermo Fisher Scientific (MA, USA). Cell Counting Kit 8 (CCK-8), Annexin V-PI cell apoptosis kit, and JC-1 kit were purchased from Yeasen Biotechnology (Shanghai, China). Thiophene-2-thiol,4,6-dia-midino-2-10 phenylindole (DAPI), Mito-Tracker green, Golgi-Tracker green, ER-Tracker green, and Lyso-Tracker green were purchased from Beyotime (Shanghai, China). All fluorescent-labeled monoclonal antibodies were obtained from Biolegend (CA, USA) and Beyotime (Shanghai, China). αPD-1 antibody was supplied from BioXcell (NH, USA) and Zinc Phthalocyanine (ZnPc, 98%) was purchased from Adamas (Shanghai, China). All other chemical reagents were purchased commercially from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).
αpd 1 antibody
Manufactured by BioXCell
Sourced in United States
The αPD-1 antibody is a laboratory reagent designed for use in research applications. It binds to the programmed cell death protein 1 (PD-1), which is an immune checkpoint receptor expressed on the surface of T cells. The core function of this antibody is to facilitate the study of the PD-1 pathway and its role in immune response regulation.
Automatically generated - may contain errors
Lab products found in correlation
Savant speedvac, by Thermo Fisher Scientific (2 mentions)
Matrigel, by Corning (2 mentions)
Isotype control antibody, by BioXCell (2 mentions)
Er tracker green, by Beyotime (1 mentions)
Jc 1 kit, by Yeasen (1 mentions)
Golgi tracker green, by Beyotime (1 mentions)
Fluorescent labeled monoclonal antibodies, by BioLegend (1 mentions)
Trypsin, by Thermo Fisher Scientific (1 mentions)
Penicillin streptomycin, by Keygen Biotech (1 mentions)
Cell counting kit 8 cck 8, by Yeasen (1 mentions)
Mito tracker green, by Beyotime (1 mentions)
Lysotracker green, by Beyotime (1 mentions)
Rmil 33, by R&D Systems (1 mentions)
5 protocols using αpd 1 antibody
1
Comprehensive ROS-sensing Protocol
2
Investigating ILC-2 Responses in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
WT or Pdcd1−/− mice were treated with rmIL-33 (R&D Systems; 200 ng/mice) or PBS for 3 d, and then lungs were isolated for ILC-2 characterization and functional phospho STAT-5 phosphorylation assays. In certain experiments, Rag1−/− mice were treated with either αPD-1 antibody (BioXcell; clone RMP1-14; 250 µg/mice/d) or mouse IgG2a isotype control. After antibody treatment, mice were treated with rm-IL-33 or PBS, and then lungs were isolated for ILC-2 characterization. For human into murine experiments, PBMCs were injected into NSG mice (4 million/mouse), followed by i.p injection of rh-IL-2 (500 ng/mouse/d), rh-IL-7 (500 ng/mouse/d), and rh-IL-33 (200 ng/mouse/d). Certain cohorts were treated with mouse isotype control (250 µg/mouse/day) and DMSO Vehicle or with αPD-1 (250 µg/mouse/d) and Tofacitinib (15 mg/kg/d/mouse) for 3 d. Lungs were harvested at day 5 after adoptive transfer, and then human ILC-2 numbers and function were evaluated.
3
Subcutaneous Tumor Xenograft Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Subcutaneous tumors were initiated by injecting tumor cells in 50% Matrigel (Corning, Bedford, MA) into the subcutaneous space on the left and right flanks of mice. Two × 105 murine PDAC cells or 5 × 105 human PDAC cells were used for each tumor. In vivo G-1 treatments were performed by first dissolving G-1, synthesized as described previously,9 in 100% ethanol at a concentration of 1 mg/mL. The desired amount of G-1 was then mixed with an appropriate volume of sesame oil, and the ethanol was evaporated off using a Savant Speed Vac (Thermo Fisher Scientific, Waltham, MA), leaving the desired amount of G-1 dissolved in 50 μL sesame oil per injection at a 10 mg/kg dose. Vehicle injections were prepared in an identical manner using 100% ethanol. Vehicle and G-1 injections were delivered through subcutaneous injection as indicated in each experimental timeline. Isotype control antibody (Clone: 2A3; BioXcell, West Lebanon, NH) and αPD-1 antibody (Clone: RMP1-14; BioXcell) were diluted in sterile phosphate-buffered saline (PBS) and delivered through intraperitoneal injections at a dose of 10 mg/kg.
4
Establishment and Treatment of Subcutaneous Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Subcutaneous tumors were initiated by injecting tumor cells in 50% Matrigel (Corning, Bedford, MA, USA) into the subcutaneous space on the left and right flanks of mice. For each type of tumor injection, 4 × 104 B16F10 cells were used, 1 × 106 WM46 cells were used, and 1 × 105 YUMM1.7 cells were used. In vivo G-1 treatments were performed by first dissolving G-1, synthesized as described previously (Natale et al., 2016 (link)), in 100% ethanol at a concentration of 1 mg/ml. The desired amount of G-1 was then mixed with an appropriate volume of sesame oil, and the ethanol was evaporated off using a Savant Speed Vac (Thermo Fisher Scientific, Waltham, MA, USA), leaving the desired amount of G-1 dissolved in 50 μL of sesame oil per injection at a 0.4 mg/kg dose for B16F10 experiments, and 10 mg/kg dose for YUMM1.7 experiments. Vehicle injections were prepared in an identical manner using 100% ethanol. Vehicle and G-1 injections were delivered through subcutaneous injection as indicated in each experimental timeline. Isotype control antibody (Clone: 2A3, BioXcell, West Lebanon, NH, USA) and αPD-1 antibody (Clone: RMP1-14, BioXcell) were diluted in sterile PBS and delivered through intraperitoneal injections at a dose of 10 mg/kg.
5
Xenograft Tumor Treatment Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
KCP cells were generated as described above. Cells (105) were suspended in Matrigel, implanted into the pancreata of 6- to 8-wk-old syngeneic mice (C57BL/6), and allowed to establish for 14–30 d before beginning treatment. Mice were randomized to four groups (10 mice/group) for each model, and treated with vehicle, SHP099, ARS, or SHP099/ARS. Investigators were not blinded to group allocation. Vehicle, ARS (200 mg/kg daily), SHP099 (75 mg/kg daily), ARS 200 mg/kg daily, or SHP099 75 mg/kg daily was administered for the indicated time, and mice were euthanized. Where indicated, α-PD-1 antibody (200 µg; Bio X Cell; RMP1-14) was used. Dosing was repeated every 3 d for the duration of the experiment. Control mice were injected with PBS or isotype control antibody (Bio X Cell; clone LTF-2).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!